May 3, 2012-NEW! ACTION!: Malaysian AIDS Council (MAC) sends letter to Ministry of Health requesting a government use license for Kaletra (links to mac.org.my)

May 3, 2012: Pharmalot: Abbott, Kaletra Pricing And AIDS in Colombia (link to pharmalot.com)

NEW! ACTION! Colombian 37th Administrative Circuit Court Judge's Sentence for "Acción Popular" (en español)
(links to communicacionpositiva.org)
Part 1   Part 2
Public Citizen: Colombian Court: Abbott Labs' AIDS Drug Pricing Abuse Violated Health Rights


March 14, 2011-
NEW! GTPI supports judicial decision annulling patent HIV/AIDS medicine (link to www.patentes.org.br)

March 9, 2012-NEW! ACTION!: Folha.com: Decisão da Justiça anula patente de droga anti-Aids (link to www1.folha.uol.com.br)
Brazilian court annuls patent on HIV/AIDS medicine (Kaletra) (in Portuguese)


January 10, 2011-ACTION! :
Abbott Laboratories responds with letter to the St. Maarten AIDS Foundation

December 21, 2011- ACTION! : Abbott Laboratories' responds with letter to the Vietnam Network of People Living with HIV

December 20, 2011- ACTION!: Working Group on International Property (GTPI) on Brazilian Patent Office's decision to prioritize examination of the patent application related to heat-stable ritonavir and lopinavir/ritonavir (links to deolhonaspatentes.org.br)

December 1, 2011- AIDS Treatment Revolution: Expand Generic Competition (links to truthout.org)

December 1, 2011- Public Citizen World AIDS Day Statement: Expanding Global AIDS Treatment Through Generic Competition

More


For more information, contact us at
medsaccess@citizen.org


Global Kaletra Campaign

A worldwide campaign to expand access to a vital HIV treatment

On November 10, public health groups in a dozen countries launched a global campaign to challenge Abbott Laboratories’ monopolistic hold on Kaletra (lopinavir+ritonavir), a critical HIV/AIDS medicine. The goal is to spur competition by generic drugmakers and thereby lower the medicine’s price, as well as to free up its components for new and improved combination treatments.

The new campaign comprises an unprecedented global effort to fight Big Pharma’s political power and improve access to lifesaving medicines

PRESS RELEASE (November 9, 2011)  English  | Español | Chinese
SUMMARY OF ACTIONS (Please find further information on each country page)


About The Campaign

Country Actions


"Acting in concert around the world, we will fight pharmaceutical monopoly abuses".--Luz Marina Umbasia, attorney for Colombian treatment groups
 
"We are launching competition campaigns in many countries so we can work together for access"--Sindi Putri, ITPC Indonesia
 
 

Country Spotlight: Vietnam

Access Story Spotlight


"Hopes that the cost of second-line treatments would fall significantly have not been realized. (...) A key driver is the cost of Abbott Lopinavir/Ritonavir products."--PEPFAR Vietnam Report
  "I wish the drug company would lower the price, as I know that the number of people taking Kaletra is growing higher and higher – and there are many more who can’t afford the treatment they need." --Naza of Malaysia's PT Foundation 
   

Back to Public Citizen Global Access to Medicines Home Page

Copyright © 2012 Public Citizen. All rights reserved. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation.
  Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.